New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
07:28 EDTTGTXTG Therapeutics added to Focus List at Roth Capital
Roth Capital added TG Therapeutics to the Focus List based on exceptions the remainder of 2104 will be transformational with upcoming data catalysts and improved visibility from the competitive landscape. Shares are Buy rated with a $15 price target.
News For TGTX From The Last 14 Days
Check below for free stories on TGTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
09:08 EDTTGTXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Chipotle (CMG), up 10.7%... Crocs (CROX), up 5%... Lockheed Martin (LMT), up 1.4%. ALSO HIGHER: GreenHunter Resources (GRH), up 10.3% after announcing intent to form MLP... TG Therapeutics (TGTX), up 9.5% after reporting Q2 results, preclinical study results, price target on shares raised to $19 from $13 at Brean Capital... FuelCell (FCEL), up 5.4% after announcing German government support, EUR 4.9M in research awards... Apache (APA), up 5.2% after Bloomberg says activist investor JANA Partners disclosed $1B position in the stock. DOWN AFTER EARNINGS: Harley-Davidson (HOG), down 4.1%... Travelers (TRV), down 3.4%... McDonald's (MCD), down 2.3%... Coca-Cola (KO), down 2.5%. ALSO LOWER: Amazon.com (AMZN), down 1% following downgrade to Neutral rating at Citigroup.
07:34 EDTTGTXTG Therapeutics price target raised to $19 from $13 at Brean Capital
Subscribe for More Information
July 21, 2014
18:40 EDTTGTXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
18:13 EDTTGTXTG Therapeutics to host conference call
Subscribe for More Information
16:30 EDTTGTXTG Therapeutics up 4.3% after reporting Q2 results, preclinical study results
16:15 EDTTGTXTG Therapeutics reports preliminary clinical results from TG-1101 Phase I study
TG Therapeutics announced preliminary clinical results from its ongoing Phase I study of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody in combination with TGR-1202, the company's novel, once-daily PI3K delta inhibitor in patients with advanced CLL and non-Hodgkin's lymphoma. 100% of CLL/SLL patients had significant nodal reduction with either a normalization of or greater than or equal to 80% reduction in Blood Lymphocyte Count. 4 of 5 CLL/SLL patients achieved a partial response at first assessment, including a patient relapsed from a prior BTK-inhibitor, and the 5th patient with stable disease achieved a 44% nodal reduction pending next assessment. 2 of 5 heavily pretreated DLBCL patients achieved a PR, including one patient with GCB subtype refractory to prior therapy. Combination appears well tolerated with no dose-related increases in toxicity observed among patients treated to date
16:13 EDTTGTXTG Therapeutics reports Q2 EPS (36c), consensus (24c)
Subscribe for More Information
07:13 EDTTGTXUniversity of Nebraska Medical Center to hold a conference
2014 Pan Pacific Lymphoma Conference to be held in Kohala Coast, Hawaii on July 21-25.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use